X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Net Income towards Common Stockholders of -$23.9 million for Q4 2025, up 19.73% on a QoQ basis from -$29.8 million in Q3 2025, and up 39.95% year-over-year from -$17.1 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$23.9 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 39.95% year-over-year to -$23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$79.2 million (down 111.42% YoY) and the FY2025 annual result came in at -$79.2 million, down 111.16% from the prior year.
- Net Income towards Common Stockholders was -$23.9 million for Q4 2025 at X4 Pharmaceuticals, up from -$29.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
- A 5-year average of -$20.8 million and a median of -$24.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 263.03% in 2024, while the deepest fall reached 1490.07% in 2024.
- X4 Pharmaceuticals' Net Income towards Common Stockholders stood at -$35.9 million in 2021, then gained by 18.96% to -$29.1 million in 2022, then jumped by 34.27% to -$19.1 million in 2023, then sank by 108.2% to -$39.8 million in 2024, then soared by 39.95% to -$23.9 million in 2025.
- Business Quant data shows XFOR's Net Income towards Common Stockholders at -$23.9 million in Q4 2025, -$29.8 million in Q3 2025, and -$25.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -23.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.92 Mn |
| Sep 30, 2025 | -29.80 Mn |
| Jun 30, 2025 | -25.75 Mn |
| Mar 31, 2025 | 276,000.00 |
| Dec 31, 2024 | -39.83 Mn |
| Sep 30, 2024 | -36.65 Mn |
| Jun 30, 2024 | 90.83 Mn |
| Mar 31, 2024 | -51.80 Mn |
| Dec 31, 2023 | -19.13 Mn |
| Sep 30, 2023 | -2.31 Mn |
| Jun 30, 2023 | -55.71 Mn |
| Mar 31, 2023 | -24.02 Mn |
| Dec 31, 2022 | -29.10 Mn |
| Sep 30, 2022 | -21.87 Mn |
| Jun 30, 2022 | -21.21 Mn |
| Mar 31, 2022 | -24.22 Mn |
| Dec 31, 2021 | -35.91 Mn |
| Sep 30, 2021 | -20.18 Mn |
| Jun 30, 2021 | -19.64 Mn |
| Mar 31, 2021 | -26.92 Mn |